Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02732327 · ClinicalTrials.gov registry record · Phase 2
Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer
A Phase 2 study, sponsored by Forest Laboratories.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT02732327 is a Phase 2 study that was terminated before completion, run by Forest Laboratories. The registered enrollment target is 2 participants.
The verdict
NCT02732327, a Phase 2 study, was terminated before completion, sponsored by Forest Laboratories.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study will evaluate the effect, safety, and tolerability of ceftazidime-avibactam (CAZ-AVI) plus vancomycin or linezolid compared to standard of care plus vancomycin or linezolid as empiric therapy in febrile neutropenic adults with cancer
Interventions
- DRUG Vancomycin
- DRUG Cefepime
- DRUG Meropenem
- DRUG Linezolid
- DRUG CAZ-AVI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2016-05-17 |
| Est. Completion | 2016-06-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02732327
The ClinicalTrials.gov registry entry for NCT02732327 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Vancomycin is the first listed.
NCT02732327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02732327 about?
NCT02732327 is a clinical study titled "Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer". This study will evaluate the effect, safety, and tolerability of ceftazidime-avibactam (CAZ-AVI) plus vancomycin or linezolid compared to standard of care plus vancomycin or linezolid as empiric therapy in febrile neutropenic adults with cancer
What is the current status of trial NCT02732327?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2016-05-17. Estimated completion is 2016-06-27.
What interventions are being tested in trial NCT02732327?
The interventions under investigation include: Vancomycin (DRUG), Cefepime (DRUG), Meropenem (DRUG), Linezolid (DRUG), CAZ-AVI (DRUG).
Who is sponsoring clinical trial NCT02732327?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.